Jazz Pharmaceuticals, Inc.
Jazz Pharmaceuticals, Inc., a prominent player in the biopharmaceutical industry, is headquartered in the United States. Founded in 2003, the company has established itself as a leader in developing innovative treatments for neurological and sleep disorders, as well as oncology. With a strong focus on rare diseases, Jazz Pharmaceuticals has made significant strides in addressing unmet medical needs. The company’s core products, including Xyrem and Sunosi, are distinguished by their unique formulations and targeted therapeutic approaches. Over the years, Jazz has achieved notable milestones, including strategic acquisitions that have expanded its product portfolio and market reach. Today, Jazz Pharmaceuticals is recognised for its commitment to improving patient outcomes and maintaining a robust position in the competitive biopharmaceutical landscape.
DitchCarbon Score
How does Jazz Pharmaceuticals, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Jazz Pharmaceuticals, Inc.'s score of 23 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Jazz Pharmaceuticals, Inc.'s reported carbon emissions
As of the latest available data, Jazz Pharmaceuticals, Inc. has not publicly reported any specific carbon emissions figures or detailed climate commitments. Without emissions data, it is challenging to assess their current environmental impact or progress towards sustainability goals. However, the absence of reported emissions does not preclude the company from engaging in climate initiatives or setting reduction targets. In the pharmaceutical industry, companies are increasingly recognising the importance of addressing climate change and may be working towards internal sustainability measures, even if these have not been formally disclosed. For stakeholders interested in Jazz Pharmaceuticals' environmental strategies, it is advisable to monitor future reports for any updates on emissions data, reduction targets, or climate commitments that may emerge as part of their corporate responsibility initiatives.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Jazz Pharmaceuticals, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
